Validation Study of Covariates Model (VaSCoM) for Propofol
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Anaesthesia for surgical procedures can be provided using a continuous infusion of intravenous drug. The most commonly used drug for this technique is propofol. Infusion devices programmed with pharmacokinetic models can be used to infuse propofol to achieve a target blood concentration. These pharmacokinetic models predict the rate of distribution of propofol within the body and also the rate at which it is cleared. In practice, the anaesthetist enters patient details such as age, sex and weight as well as a target blood concentration of propofol. The infusion device then infuses propofol at the appropriate rate to achieve this concentration.
White and colleagues recently published the Covariates Model for propofol. It is anticipated that this model will have reduced bias and inaccuracy compared to the models in current clinical use. The VaSCoM study has three objectives:
- Prospective validation of the Covariates Model
- Modelling of the effect site concentration of propofol
- Comparison of propofol concentration in venous and arterial blood samples
To achieve the above objectives, patients over 18 years of age and undergoing elective non-cardiac surgery will be recruited to the study. Anaesthesia will be delivered using a target controlled infusion device programmed with the Covariates Model for propofol. The target blood concentrations will be set according to a pre-determined schedule and all measurements will be made prior to the start of surgery.
Prospective validation of the Covariates Model will be done by comparing blood concentration of propofol predicted by the model to those actually measured. These results will then be compared to the predictions made using the models in current clinical practice.
Modelling of the effect site means predicting the concentration of propofol in the brain for a given blood concentration. This will involve using depth of anaesthesia monitors (such as bispectral index) as surrogate markers of brain concentration and comparing this to the predicted and measured blood concentrations of propofol.
Finally, important information on the distribution and clearance of propofol can be gained through the comparison of venous and arterial blood samples. In this study, simultaneous sampling of venous and arterial blood will facilitate this comparison.
| Condition | Intervention |
|---|---|
|
Target Controlled Infusion of Propofol |
Drug: Propofol |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) |
| Official Title: | Validation Study of Covariates Model (VaSCoM) for Propofol |
- Performance error of predicted blood propofol concentration (venous blood samples) [ Time Frame: 1.5, 5, 16.5, 20, 31.5, 35, 45-60 minutes post infusion start time ] [ Designated as safety issue: Yes ]
Performance error is calculated as:
((Measured blood concentration - Predicted blood concentration)/ Predicted blood concentration) x 100
The median performance error and the absolute performance error can then be calculated as measures of bias and inaccuracy respectively.
- Depth of anaesthesia [ Time Frame: 0 to 45-60 minutes post infusion start time ] [ Designated as safety issue: No ]Depth of anaesthesia (as measured by bispectral index and index of consciousness) will be used as a surrogate marker of propofol effect site concentration. By using complex statistical analysis to compare depth of anaesthesia to measured and predicted blood concentrations, we aim to determine the Keo. This is the rate constant for elimination of propofol from the effect site compartment and will be incorporated to the Covariates Model to predict brain concentration for a given blood concentration of propofol.
- Comparison of performance errors calculated from venous blood samples to performance errors calculated from arterial blood samples [ Time Frame: 1.5, 5, 16.5, 20, 31.5, 35, 45-60 minutes post infusion start time ] [ Designated as safety issue: No ]
Performance error is calculated as:
((Measured blood concentration - Predicted blood concentration)/ Predicted blood concentration) x 100
| Estimated Enrollment: | 30 |
| Study Start Date: | January 2011 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Low-high-low blood target concentration
Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
|
Drug: Propofol
Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
|
|
Experimental: High-low-high target blood concentration
Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
|
Drug: Propofol
Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aged over 18 years
- ASA I/II
- Elective non-cardiac surgery expected to last longer than 30 minutes
Exclusion Criteria:
- Patient refusal or unable to consent
- Premedication, sedative or anaesthetic in the previous 12 hours
- Pre-operative GCS less than 15
- ASA III/IV
- Allergy to constituents of propofol
- Excess alcohol intake
- Drug abuse
- Mental retardation
- Difficult airway
- BMI over 35
Contacts and Locations| Contact: Stefan Schraag | 00441419515609 | stefanschraag@btinternet.com |
| United Kingdom | |
| Golden Jubilee National Hospital | Recruiting |
| Clydebank, United Kingdom, G81 4HX | |
| Contact: Stefan Schraag 00441419515609 stefanschraag@btinternet.com | |
| Principal Investigator: Stefan Schraag | |
| Principal Investigator: | Stefan Schraag | Golden Jubilee National Hospital |
More Information
No publications provided
| Responsible Party: | Golden Jubilee National Hospital |
| ClinicalTrials.gov Identifier: | NCT01492712 History of Changes |
| Other Study ID Numbers: | VaSCoM005, 2009-017900-10 |
| Study First Received: | December 8, 2011 |
| Last Updated: | December 15, 2011 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Keywords provided by Golden Jubilee National Hospital:
|
Propofol Pharmacokinetics Pharmacodynamics Infusion Pumps |
Additional relevant MeSH terms:
|
Propofol Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Hypnotics and Sedatives |
ClinicalTrials.gov processed this record on May 16, 2013